DO NOT TRUST ALPHA CARDINAL, STANFORD, Lu Chen, Yuk-Chien Liu, Suraj Pradhan, Erik Pettersson
ALPHA CARDINAL writes in a Seeking Alpha article bashing Osiris. They write the following: "Although its Prochymal development partner, Sanofi (SNY), broke ties with Osiris in 2011, Osiris has now partnered with Swiss-based biotech Lonza..."
This is TOTAL hog wash!
The Lonza deal with Osiris has been ongoing since 2008, well before 2011. GET YOUR FACTS STRAIGHT BEFORE YOU BASH ALPHA CARDINAL!
These Stanterd postdoc and MSc students are bashing Osiris...you have to ask why? Every sentence they write is negative. Osiris can do no right according to them.
They cite competition as a MAJOR obstacle to Osiris success BUT TOTALLY FAIL to acknowledge that Osiris won its patent challenge in Australia against Mesoblast and now has ophan drug status in Europe. This is a game changer! The SPACE IS NOT CROWDED WHEN YOU WIN GUYS!
Jul 1, 2008
Lonza Reports Manufacturing Deal with Osiris and Facility Constructions
Lonza signed a clinical and commercial manufacturing agreement with Osiris Therapeutics for Prochymal®, Osiris’ adult stem cell therapy. Prochymal is being evaluated in Phase III trials for acute and steroid-refractory graft-versus-host disease and Crohn's disease.
Lonza also announced the construction of new facilities including the first commercial-scale allogeneic cGMP manufacturing plant and additional capacity to produce cGMP-grade cell culture media for therapeutic applications. This will provide Lonza the capacity to manufacture the tens of billions of cells per day needed to support its clients’ commercialization efforts, say Lonza officials.